Resilient HIV Implementation Science With SGM Youths Using Evidence

N/AEnrolling By InvitationNCT06350682

University of Maryland, Baltimore1,500 enrolled

Overview

The Resilient HIV Implementation Science with SGM Youths using Evidence (RISE) Clinical Research Center will use a Type 2 hybrid-effectiveness-implementation study to evaluate the effectiveness and implementation of HMP, a youth-tailored digital health platform. It is hypothesized that SGM youths in the HMP intervention group will demonstrate improved PrEP initiation and viral load suppression over 12 months compared to the delayed HMP group.

RISE is a randomized control trial where participants are randomized (1:1) to either healthMPower (HMP) exposure for a 12 month period or delayed access to the HMP within 8 strata based on the serostatus group. HIV seropositive and HIV seronegative at risk, age group 15 to 17 or 18 to 24 years of age and country either Nigeria, Kenya, Malawi, or Zambia. Within the strata of serostatus, age, and country, participants will be randomly assigned to the next treatment allocation from a randomly permuted block sequencing using block size of four. 750 Participants will be randomly assigned to the HMP exposure while the other 750 participants will have delayed access to HMP. The HMP is a culturally adapted status neutral mobile app that works to address HIV prevention to care continuum (PHCC) for SGM youth at each of the CBSPs. Participants who are delayed access for 12 months will be granted "Open access" for 12 months thereafter, when compared to participants who were provided access for 12 months then provided 12 months of access called "continued access" without other external support. Therefore, participants will either be provided access for 12 or 24 months depending on the randomization. Primary outcome, clinical effectiveness endpoint for HIV seronegative at risk young will be the uptake of PrEP and for HIV seropositive viral load suppression. Secondary outcome, PHCC pathway characterized for HIV seronegative at risk youth such as PrEP education and continuation and for HIV seropositive HIV testing, linkage, and ART initiation.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

SINGLE

Enrollment

1,500

Conditions

Hiv

Interventions

HealthMPowerment (HMP)BEHAVIORAL

Participants will be provided access to the status neutral platform (HMP)mobile app for 12 months exposure period or a delayed access period. The HMP is developed specific to RISE and will be adapted based off feedback from each local site via stakeholders/YABs. The HMP will encompass a range of features including a robust content management system and back end administrative dashboard, multi media resources and information center, social support features such as connections to peers and providers, interactive activities and self assessments, and flexible medication and health trackers. In addition the app will support HIV/STI test kit ordering and results portal and a gamified reward system. With real time analytics to monitor user engagement and response with the DHI we can adapt the delivery of tailored content to fit emergent HIV prevention and care challenges.

Eligibility

Sex: MALEMin age: 15 YearsMax age: 24 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Male sex at birth * Age 15-24 years * Own an Android or iOS smartphone * Had receptive or insertive sex with another man in the past 12 months * Receiving care or prevention services at the CBSP-associated with the CRPS at the time of study. Exclusion Criteria: * Less than 15 years old * Greater than 24 years old * Inability or cognitively impaired to provide consent * Does not own an Android or iOS smartphone.

Locations (3)

Icarh/Ihvn

Abuja, Nigeria, Nigeria

Centre for Population Health Initiative

Lagos, Nigeria, Nigeria

CIHEB Zambia Limited

Lusaka, Zambia, Zambia

Outcomes

Primary Outcomes

PrEP initiation for HIV seronegative seropositive

For those HIV seronegative, initiation of pre-exposure prophylaxis (PrEP) (Oral PrEP dispensed by pharmacy or Long-acting injectable defined as receiving first dose)

Time frame: 24 months

Viral load suppression for HIV

HIV seropositive viral load suppression at 12 months of taking ART (defined as HIV viral load of less than 1,000 copies/mL)

Time frame: 24 months

RE-AIM

Implementation Effectiveness on reach (characteristics of participants enrolled), Adoption (HMP physician and client interaction), Implementation (barriers and facilitators), Maintenance (HMP immediate access group at 21-24 months) and cost effectiveness of the HMP (incremental costs effectiveness ration and net monetary benefit)

Time frame: 24 months

Secondary Outcomes

HIV testing cascade

HIV self testing

Time frame: 12-24 months

PrEP continuum

PrEP education (restart/re-initiation)

Time frame: 12-24 months

HIV care and treatment continuum

For those HIV seropositive, antiretroviral treatment (ART) initiation and retention at 12 months

Time frame: 12-24 months

Implementation effectiveness

Study retention (participants who remained active at 24 months)

Time frame: 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.